

TITLE: Preparation of N-glycyl-2-cyanopyrrolidines as DPP IV inhibitors  
 INVENTOR(S): Villhauer, Edwin Bernard  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SOURCE: PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096295	A2	20011220	WO 2001-EP6595	20010611
WO 2001096295	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
TW 583185	B	20040411	TW 2001-90113972	20010608
CA 2411778	A1	20011220	CA 2001-2411778	20010611
EP 1296974	A2	20030402	EP 2001-984014	20010611
EP 1296974	B1	20090805		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004503531	T	20040205	JP 2002-510439	20010611
AT 438639	T	20090815	AT 2001-984014	20010611
US 6432969	B1	20020813	US 2001-879654	20010612
US 20020193390	A1	20021219	US 2002-176440	20020620
PRIORITY APPLN. INFO.:			US 2000-325743P	P 20000613
			US 2000-592336	A 20000613
			WO 2001-EP6595	W 20010611
			US 2001-879654	A3 20010612

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 136:37503

AB The present invention relates to the preparation of N-(substituted glycyl)-2-cyanopyrrolidines. Thus, 1-chloroacetyl-2-(S)-cyanopyrrolidine (synthetic preparation given) is reacted with 2-[(5-chloro-2-pyridinyl)amino]-1,1-dimethylethylamine in the presence of K<sub>2</sub>CO<sub>3</sub> to give 1-[[[2-[(5-chloro-2-pyridinyl)amino]-1,1-dimethylethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine. The prepared compds. inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance. Data for biol. activity of some of the prepared compds. were given.

IT 380831-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological activity); PREP (Preparation); USES (Uses)


(preparation of N-glycyl-2-cyanopyrrolidines as DPP IV inhibitors)

RN 380831-65-2 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[2-[[4-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]cyclohexyl]amino]acetyl]-, hydrochloride (1:2), (2S)-

(CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl